Health CanadaGeneral Alert
IMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For the Public
Published: November 19, 2014Recall ID: 52884Category: generalCountry: Canada
Safety AlertHealth Canada
Canada
IMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For the Public
Recalling Firm: Marketed health products
Reason for Recall / Hazard
Product safety
Product Description & Identification
IMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For the Public
Additional Source Details
| Field | Value |
|---|---|
| N I D | 52884 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/imovane-zopiclone-new-dosage-recommendations-minimize-risk-next-day-impairment-public |
| Issue | Product safety |
| Title | IMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For the Public |
| Archived | 1 |
| Category | Drugs |
| Last updated | 2014-11-19 |
| Organization | Marketed health products |
Check Other Products In Your Household
Free Safety ToolsSafety recalls are issued daily across foods, medications, vehicles, and electronics. Use our instant tools to check your home for active safety warnings:
Overview
- Recalling FirmMarketed health products
Recall Hazard Severity
Official Agency AlertCaution (Class III)
📢 Share Warning
Alert family and friends to keep them safe. Copy this quick alert message:
🚨 SAFETY ALERT: Marketed health products - IMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For the Public Check if your household is affected: https://therecallfile.com/recalls/imovane-zopiclone-new-dosage-recommendations-to-minimize-the-risk-of-n/CANADA-52884
Join Alertlist
Get instant email updates whenever critical safety recalls like this are published.
Support The Recall File
Help keep official recall alerts free, accessible, and fast for everyone.
Spread the WordIMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For the Public